Navigation Links
Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay
Date:3/20/2012

rs: (i) Nektar's drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; and (iv) certain other important risks and uncertainties set forth in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2012. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Nektar Investor Inquiries:
Jennifer Ruddock/Nektar Therapeutics                                 (415) 482-5585
Susan Noonan/SA Noonan Communications,
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Hologic, Inc. (NASDAQ: HOLX ), today ... Chief Executive Officer, will preside over the NASDAQ Stock ... day of Breast Cancer Awareness Month. In his remarks, ... the important benefits of Hologic,s 3D Mammography technology, the ... superior to traditional mammography. This is the ...
(Date:9/30/2014)... , Sept. 30, 2014 This study ... molecular imaging informatics solutions including nuclear imaging informatics, ... comparison. The study assesses the size of the ... and 2013, and projects future growth based on ... the dynamics taking place in the broader markets ...
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
(Date:10/1/2014)... October 01, 2014 Lifeinsurance-policy.com has ... the best life insurance prices for smokers. , Smoking ... insurance premiums. Comparing quotes is the best method to ... quotes for customers who need coverage. , Whole ... duration of the policy. Since the coverage is permanent, ...
(Date:10/1/2014)... Join the more than 80 golfers who already have ... charity golf tournament to benefit Project HEAL, a not-for-profit organization ... afford treatment. The tournament will be held Monday, Oct. 6, ... The day-long event starts with 10:30 a.m. check-in and shotgun ... begin at 5 p.m. and will include an auction featuring ...
(Date:10/1/2014)... City, NJ (PRWEB) October 01, 2014 Diet ... with their intentions to lose weight and their dieting attempts ... unhealthy, fatty foods. Including hormone diet treatments into ... only allows patients to see fast and effective weight loss ... and begin forming healthy habits to maintain their weight for ...
(Date:10/1/2014)... occasion of the Leishmaniasis East Africa Platform meeting, ... leishmaniasis experts, results of a pharmacovigilance or ... carried out by MSF, DNDi, and national partners ... to key decision makers in order to boost ... combination of Sodium Stibogluconate and Paromomycin (SSG&PM) in ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2
... ... of MD Anderson will be conducting a lecture on Radiation Therapy Options for Mesothelioma patients. ... ... -- Mesothelioma lecture on Tuesday November 10th, 2009, 5:30 pm CST, MesoCare.org is ...
... ... collaborating to provide Davis Applied Technology College with a working showroom of CNC machines. ... Okuma open-architecture THINC control. Grand Opening January 12-14, 2010. , ... Charlotte, NC (PRWEB) November 9, 2009 ...
... HUYA Bioscience International, a leader in ... partnership with the School of Medicine and Pharmacy, ... in a series of collaborations that HUYA has ... to enable and accelerate the global development and ...
... Nov. 8 Today, the nation Mayors commended the ... Care for America Act, a historic piece of legislation, ... , In June, at the US Conference of Mayors ... nation unanimously supported the health care reform principles of ...
... finds , SUNDAY, Nov. 8 (HealthDay News) -- Your mother ... up straight: New research suggests that good posture could make ... of us were taught that sitting up straight gives a ... study and a psychology professor at Ohio State University, said ...
... Nov. 7 Tonight the House of Representatives passed ... reform legislation that will ensure every American has access ... The legislation, which cracks down on some of the ... million Americans and cut the deficit by $104 billion ...
Cached Medicine News:Health News:Okuma America Corporation & Hartwig, Inc. to Provide Machines to Davis Applied Technology College for Machine Tool Technology Program 2Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:The Nation's Mayors Commend House Passage of Health Reform Bill 2Health News:Good Posture May Inspire Confidence 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3
... magnification and increased stereopsis, the ... for detailed visualization to the ... is ideal for vitrectomy in ... in proliferative vitreoretinopathy extending to ...
... Volks Reinverting Operating Lens System® ... advanced wide angle viewing system ... Its unique single-element prism design, ... wide-field viewing capability have made ...
... The new Volk Blumenthal Suturelysis ... flap sutures, enabling cutting sutures which, ... relatively inaccessible. The lens provides localized ... of the suture 2-3 times, resulting ...
... Laser capsulotomy procedures are now greatly improved ... Lens. This new lens promotes precise and ... bag. Computer optimized for enhanced viewing and ... new aspheric design comes standard with LaserWindow ...
Medicine Products: